Frazier Financial Advisors LLC Sells 30 Shares of Stryker Co. (NYSE:SYK)

Frazier Financial Advisors LLC trimmed its position in Stryker Co. (NYSE:SYK) by 5.9% in the third quarter, according to its most recent filing with the SEC. The institutional investor owned 475 shares of the medical technology company’s stock after selling 30 shares during the period. Frazier Financial Advisors LLC’s holdings in Stryker were worth $172,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Centennial Bank AR grew its position in Stryker by 106.7% in the 2nd quarter. Centennial Bank AR now owns 93 shares of the medical technology company’s stock worth $32,000 after purchasing an additional 48 shares in the last quarter. HBW Advisory Services LLC bought a new stake in Stryker in the 3rd quarter worth about $42,000. Hara Capital LLC purchased a new position in Stryker in the third quarter valued at about $42,000. Grove Bank & Trust boosted its stake in Stryker by 84.8% in the third quarter. Grove Bank & Trust now owns 122 shares of the medical technology company’s stock valued at $44,000 after acquiring an additional 56 shares during the last quarter. Finally, DT Investment Partners LLC boosted its stake in Stryker by 114.3% in the third quarter. DT Investment Partners LLC now owns 135 shares of the medical technology company’s stock valued at $49,000 after acquiring an additional 72 shares during the last quarter. 77.09% of the stock is owned by institutional investors.

Stryker Stock Performance

NYSE SYK opened at $390.08 on Friday. Stryker Co. has a 1 year low of $282.35 and a 1 year high of $392.70. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.91 and a quick ratio of 1.22. The stock has a market capitalization of $148.71 billion, a PE ratio of 41.81, a P/E/G ratio of 2.94 and a beta of 0.91. The company’s 50 day simple moving average is $364.07 and its two-hundred day simple moving average is $347.40.

Stryker (NYSE:SYK) last posted its earnings results on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.77 by $0.10. Stryker had a net margin of 16.34% and a return on equity of 23.07%. The business had revenue of $5.49 billion for the quarter, compared to analysts’ expectations of $5.37 billion. During the same period in the prior year, the company posted $2.46 EPS. The business’s revenue for the quarter was up 11.9% compared to the same quarter last year. Analysts predict that Stryker Co. will post 12.06 earnings per share for the current fiscal year.

Insider Transactions at Stryker

In other news, insider Viju Menon sold 600 shares of the stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $355.00, for a total value of $213,000.00. Following the transaction, the insider now owns 9,069 shares of the company’s stock, valued at $3,219,495. This represents a 6.21 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Kevin Lobo sold 57,313 shares of the stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $368.70, for a total transaction of $21,131,303.10. Following the completion of the transaction, the chief executive officer now directly owns 100,027 shares in the company, valued at $36,879,954.90. The trade was a 36.43 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 67,381 shares of company stock valued at $24,825,275 in the last quarter. Insiders own 5.90% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on SYK shares. BTIG Research boosted their target price on shares of Stryker from $383.00 to $394.00 and gave the company a “buy” rating in a research note on Wednesday, October 30th. Citigroup boosted their target price on shares of Stryker from $406.00 to $411.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. Wolfe Research started coverage on shares of Stryker in a research note on Tuesday, September 10th. They issued an “outperform” rating and a $405.00 target price on the stock. Needham & Company LLC boosted their target price on shares of Stryker from $393.00 to $409.00 and gave the company a “buy” rating in a research note on Wednesday, October 30th. Finally, Royal Bank of Canada boosted their target price on shares of Stryker from $386.00 to $400.00 and gave the company an “outperform” rating in a research note on Wednesday, October 30th. Four research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $393.65.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.